Regencell Bioscience Holdings Ltd

NASDAQ RGC

Download Data

Regencell Bioscience Holdings Ltd Book Value Per Share 3 year CAGR for the Trailing 12 Months (TTM) ending September 30, 2023

Regencell Bioscience Holdings Ltd Book Value Per Share 3 year CAGR is NA for the Trailing 12 Months (TTM) ending September 30, 2023. The book value per share represents the net value of a company allocated to each outstanding share of common stock. It is calculated by dividing shareholders' equity by the weighted average number of shares outstanding. The book value per share provides insight into the intrinsic value of a company's shares and can be used to assess the relative value of a stock compared to its market price. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Regencell Bioscience Holdings Ltd Book Value Per Share for the Trailing 12 Months (TTM) ending December 31, 2021 was 10,250,351.68, a 4,341,618,541.27% change year over year.
  • Regencell Bioscience Holdings Ltd Book Value Per Share for the Trailing 12 Months (TTM) ending December 31, 2020 was -0.24, a 95.60% change year over year.
  • Regencell Bioscience Holdings Ltd Book Value Per Share for the Trailing 12 Months (TTM) ending December 31, 2017 was -5.37, a 2.25% change year over year.
  • Regencell Bioscience Holdings Ltd Book Value Per Share for the Trailing 12 Months (TTM) ending December 31, 2016 was -5.49.
NASDAQ: RGC

Regencell Bioscience Holdings Ltd

CEO Mr. Yat-Gai Au
IPO Date July 16, 2021
Location Hong Kong
Headquarters First Commercial Building, Causeway Bay, Hong Kong
Employees 12
Sector Healthcare
Industry Drug manufacturers - specialty & generic
Description

Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder, as well as infectious diseases. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Similar companies

EGRX

Eagle Pharmaceuticals Inc

NA

NA

PAHC

Phibro Animal Health Corporation

NA

NA

PROC

Procaps Group SA

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email